CompletedNCT05326347
What is this study about?Researchers studied OPC-34712FUM/ Brexpiprazole fumarate, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
In Kure-shiSchizophreniaMedication studyAges 18–74
- Countries
- Japan
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
CompletedNCT01625897
Official study titleA Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
This study has finished and is no longer accepting participants.
In Aizu-WakamatsuSchizophreniaMedication studyAges 20–74
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
CompletedNCT01626885
Official study titleA Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
This study has finished and is no longer accepting participants.
In KurayoshiSchizophreniaMedication studyAges 20–64
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
CompletedNCT03260257
Official study titleEnhancing Gamma Band Response in Schizophrenia to Improve Working
This study has finished and is no longer accepting participants.
In La JollaSchizophreniaInterventional studyAges 18–65
- Countries
- United States
- Sponsor
- University of California, San Diego
TerminatedNCT03900754
This study ended early.
Multiple locations, including San FranciscoSchizophreniaMedication studyAges 18–70
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
CompletedNCT01626859
Official study titleA Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)
This study has finished and is no longer accepting participants.
In SakaiSchizophreniaMedication studyAges 20–64
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
CompletedNCT04158687
What is this study about?This study evaluated the safety and effectiveness of CTP-692 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Concert Pharmaceuticals
CompletedNCT01614899
What is this study about?Researchers compared SM-13496 40mg, SM-13496 80mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Tokyo, EtcSchizophreniaMedication studyAges 18–74
- Countries
- Japan, Malaysia, South Korea, + 1 other
- Sponsor
- Sumitomo Pharma Co., Ltd.
CompletedNCT01452919
Official study titleA Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including OaklandSchizophreniaMedication studyAges 18–65
- Countries
- United States, Greece
- Sponsor
- Denovo Biopharma LLC
CompletedNCT06791122
Official study titleA Multicenter, Pragmatic Study to Evaluate Clinical Effectiveness, Engagement With the Study App, Healthcare Resource Utilization, and Safety of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including ImperialSchizophreniaDevice studyAges 18+
- Countries
- United States
- Sponsor
- Boehringer Ingelheim
CompletedNCT05693935
What is this study about?Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–64
- Countries
- United States, Bulgaria, China, + 2 others
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
CompletedNCT01051531
What is this study about?Researchers studied Paliperidone palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including DandenongSchizophreniaMedication studyAges 18–50
- Countries
- Australia, New Zealand, China, + 5 others
- Sponsor
- Janssen Research & Development, LLC